Glenmark Pharmaceuticals' subsidiary, Glenmark Speciality S.A., has entered into distribution and license agreements for Winlevi (clascoterone cream 1 percent) in certain regions.
Cassiopeia, a subsidiary of Cosmo Pharmaceuticals, is granting Glenmark exclusive rights for the commercialization of Winlevi in specific territories.
Cassiopea will oversee the process of Centralized Marketing Authorization at the European Medicines Agency (EMA) for Winlevi.
Glenmark will be responsible for handling product registration in South Africa and the UK, furthering its commercialization efforts.2.
Cosmo Pharmaceuticals will be the sole supplier of the Winlevi product in the designated regions.
As part of the collaboration, Cassiopea will receive an initial payment of $5 million.
In addition to the initial payment, Cassiopea is entitled to receive future double-digit regulatory and sales milestone payments.